Literature DB >> 10637490

Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles.

K Uozumi1, M Otsuka, N Ohno, T Moriyama, S Suzuki, S Shimotakahara, I Matsumura, S Hanada, T Arima.   

Abstract

A new factor-independent megakaryoblastic cell line, designated SET-2, was established from the peripheral blood of a patient with leukemic transformation of essential thrombocythemia (ET). SET-2 expressed CD 4, 7, 13, 33, 34, 36, 38, 41, 61, 71, 117, 126, 130 and c-mpl. In addition, it spontaneously produced numerous platelet-like particles in liquid culture. These particles were shown to be the same size as normal platelets, and to express CD 36, 38, 41, 61 and 71. Proliferation of SET-2 was not influenced by thrombopoietin (TPO) and other hemopoietic cytokines. SET-2 was found to express the platelet-specific proteins such as platelet factor 4 and beta-thromboglobulin. The levels of expression were not altered by TPO. SET-2 also secreted interleukin-6 into the supernatants, as well as normal megakaryocytes. These results suggest that SET-2 spontaneously matures to megakaryocytes and produces platelet-like particles. These findings indicate that SET-2 may be useful for investigating the proliferation and differentiation mechanisms of leukemia cells and the role of c-mpl on megakaryoblasts, megakaryocytes, and platelets in ET. Leukemia (2000) 14, 142-152.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10637490     DOI: 10.1038/sj.leu.2401608

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  17 in total

1.  Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model.

Authors:  Antônio Bruno Alves-Silva; Bruna Alves Fenerich; Natasha Peixoto Fonseca; Jaqueline Cristina Fernandes; Juan Luiz Coelho-Silva; Diego Antonio Pereira-Martins; Thiago Mantello Bianco; Priscila Santos Scheucher; Eduardo Magalhães Rego; Fernando Chahud; João Agostinho Machado-Neto; Lorena Lôbo Figueiredo-Pontes; Fabiola Traina
Journal:  Invest New Drugs       Date:  2022-01-11       Impact factor: 3.651

2.  LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms.

Authors:  Christian Marinaccio; Praveen Suraneni; Hamza Celik; Andrew Volk; Qiang Jeremy Wen; Te Ling; Marinka Bulic; Terra Lasho; Richard P Koche; Christopher A Famulare; Noushin Farnoud; Brady Stein; Michael Schieber; Sandeep Gurbuxani; David E Root; Scott T Younger; Ronald Hoffman; Naseema Gangat; Panagiotis Ntziachristos; Navdeep S Chandel; Ross L Levine; Raajit K Rampal; Grant A Challen; Ayalew Tefferi; John D Crispino
Journal:  Cancer Discov       Date:  2021-02-12       Impact factor: 39.397

3.  Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.

Authors:  Joëlle Rubert; Zhiyan Qian; Rita Andraos; Daniel A Guthy; Thomas Radimerski
Journal:  BMC Cancer       Date:  2011-01-19       Impact factor: 4.430

4.  Compartmentalized megakaryocyte death generates functional platelets committed to caspase-independent death.

Authors:  Murray C H Clarke; John Savill; David B Jones; Brendon S Noble; Simon B Brown
Journal:  J Cell Biol       Date:  2003-02-17       Impact factor: 10.539

5.  The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways.

Authors:  Bruno A Cardoso; Hélio Belo; João T Barata; António M Almeida
Journal:  PLoS One       Date:  2015-12-01       Impact factor: 3.240

6.  AKT is a therapeutic target in myeloproliferative neoplasms.

Authors:  I Khan; Z Huang; Q Wen; M J Stankiewicz; L Gilles; B Goldenson; R Schultz; L Diebold; S Gurbuxani; C M Finke; T L Lasho; P Koppikar; A Pardanani; B Stein; J K Altman; R L Levine; A Tefferi; J D Crispino
Journal:  Leukemia       Date:  2013-06-10       Impact factor: 11.528

7.  Differentiation and cell density upregulate cytochrome c levels in megakaryoblastic cell lines: Implications for analysis of CYCS-associated thrombocytopenia.

Authors:  Lily Ong; Kirstin O McDonald; Elizabeth C Ledgerwood
Journal:  PLoS One       Date:  2017-12-29       Impact factor: 3.240

8.  JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines.

Authors:  Wanke Zhao; Yanhong Du; Wanting Tina Ho; Xueqi Fu; Zhizhuang Joe Zhao
Journal:  Exp Hematol Oncol       Date:  2012-06-21

9.  Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.

Authors:  Qiang Jeremy Wen; Qiong Yang; Benjamin Goldenson; Sébastien Malinge; Terra Lasho; Rebekka K Schneider; Lawrence J Breyfogle; Rachael Schultz; Laure Gilles; Priya Koppikar; Omar Abdel-Wahab; Animesh Pardanani; Brady Stein; Sandeep Gurbuxani; Ann Mullally; Ross L Levine; Ayalew Tefferi; John D Crispino
Journal:  Nat Med       Date:  2015-11-16       Impact factor: 53.440

10.  Identification of AIM2 as a downstream target of JAK2V617F.

Authors:  Ei Leen Liew; Marito Araki; Yumi Hironaka; Seiichi Mori; Tuan Zea Tan; Soji Morishita; Yoko Edahiro; Akimichi Ohsaka; Norio Komatsu
Journal:  Exp Hematol Oncol       Date:  2016-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.